MAPT and Alzheimer disease: Understanding AD subtypes through their specific biomarkers would increase the precision of diagnoses, allowing for tailored interventions and aiding in the creation of novel therapies for subtypes that might not react favorably to conventional amyloid/tau-targeting strategies.